Journal of Crohn's & colitis · 2026
TWEAK is increased in ulcerative colitis and contributes to fibroblast-mediated monocyte activation via heterologous non-canonical NF-kB/STAT3 signaling.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matellan Carlos, Raphael Bella, Jones Gareth R, Nwaeziegwe Mary, Balfe Sarah, Ohlendieck Cian M, Bauset Cristina, Ní Chathail Méabh B, Kennedy Ciarán, Doogan Katie, Winter Des, Aherne Carol M, Roche Helen M, Bain Calum C, Thorpe Stephen D, Doherty Glen, Manresa Mario C
Аннотация
BACKGROUND AND AIMS: Interactions between fibroblasts and monocytes have emerged as a contributing factor in inflammatory bowel disease (IBD) pathogenesis and therapy resistance, owing to the ability of both cell types to participate in tissue inflammation and repair. We have previously shown that the tumor necrosis factor superfamily member TWEAK (TNFSF12) can induce an ulcerative colitis (UC)-like inflammatory profile in colonic fibroblasts in vitro, in turn promoting monocyte adhesion and activation. However, the mechanisms underlying fibroblast-monocyte communication and its dysregulation in ulcerative colitis are incompletely understood.
METHODS: Here we use co-culture models, human biopsies from UC patients and healthy donors, and public single-cell transcriptomics to characterize the mechanisms underlying fibroblast-mediated monocyte activation.
RESULTS: We show that TWEAK-treated inflammatory fibroblasts induce a transcriptional program that resembles early monocyte/macrophage intermediates in UC and is enriched for genes associated with resistance to anti-TNF (TREM1, OSM, IL1B) and susceptibility to IBD (NOD2, ATG16L1). We find that conditioned media from TWEAK-treated fibroblasts causes a sustained activation of STAT3 phosphorylation in monocytes, and that inhibition of the NF-κB inducing kinase (NIK) impairs the ability of inflammatory fibroblasts to activate STAT3 phosphorylation in monocytes, resulting in reduced expression of inflammatory mediators. Using tissues from UC patients, we show that the expansion of CD90+/PDPN+ inflammatory fibroblasts and increased FN14 in UC correlates with the accumulation of TWEAK+ myeloid cells in the colonic mucosa, and that these fibroblasts co-localize with infiltrating monocytes in sites of active inflammation.
CONCLUSION: Together, our findings suggest that the TWEAK/NF-κB/STAT3 axis represents an attractive target to tune inflammatory stroma/monocyte crosstalk.
METHODS: Here we use co-culture models, human biopsies from UC patients and healthy donors, and public single-cell transcriptomics to characterize the mechanisms underlying fibroblast-mediated monocyte activation.
RESULTS: We show that TWEAK-treated inflammatory fibroblasts induce a transcriptional program that resembles early monocyte/macrophage intermediates in UC and is enriched for genes associated with resistance to anti-TNF (TREM1, OSM, IL1B) and susceptibility to IBD (NOD2, ATG16L1). We find that conditioned media from TWEAK-treated fibroblasts causes a sustained activation of STAT3 phosphorylation in monocytes, and that inhibition of the NF-κB inducing kinase (NIK) impairs the ability of inflammatory fibroblasts to activate STAT3 phosphorylation in monocytes, resulting in reduced expression of inflammatory mediators. Using tissues from UC patients, we show that the expansion of CD90+/PDPN+ inflammatory fibroblasts and increased FN14 in UC correlates with the accumulation of TWEAK+ myeloid cells in the colonic mucosa, and that these fibroblasts co-localize with infiltrating monocytes in sites of active inflammation.
CONCLUSION: Together, our findings suggest that the TWEAK/NF-κB/STAT3 axis represents an attractive target to tune inflammatory stroma/monocyte crosstalk.